A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.

Date publication

janvier 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39673834

Résumé

Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.

Mots clés

Adjuvant therapy, Checkpoint inhibitors, Distant metastasis-free survival, Overall survival, Relapse-free survival, Stage III, Targeted therapy

Référence

Eur J Cancer. 2025 01 17;215:115160